Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Aventis</strong> Human Vaccines<br />
Pediatric combination vaccines<br />
The components of these vaccines<br />
vary because of diverse immunization<br />
schedules throughout the world.<br />
Protecting against up to six diseases,<br />
this group of products is anchored<br />
by acellular pertussis components in<br />
general and by the trivalent vaccine<br />
Daptacel in particular. Daptacel, which<br />
also protects against diphtheria and<br />
tetanus, was launched in 2002 and<br />
has become a strong sales contributor<br />
due to its synergy with immunization<br />
schedules. Pentacel, a new vaccine<br />
against fi ve diseases that has been a<br />
standard of preventive care in Canada<br />
since its launch in 1997, is registered<br />
in nine countries. Tripedia, also for the<br />
prevention of pertussis, diphtheria and<br />
tetanus, and ActHib for the prevention of<br />
Haemophilus infl uenzae type b, are two<br />
further important growth drivers within<br />
the pediatric product line. Pediacel, an-<br />
other acellular pertussis-based pentavalent<br />
vaccine, was registered in the UK in<br />
2002 and is expected to be launched in<br />
this country and parts of Latin America<br />
and east Asia in 2004.<br />
>> 25
Change language